The downgrade from Buy to Hold and the significant reduction in the price target from $16 to $5 by EF Hutton analyst Tony Butler indicate a less optimistic outlook for Rain Oncology. This could lead to a negative short-term impact on the stock price as investors may reevaluate their positions based on the new rating and price target.